2020年儿童普种甲肝疫苗:一剂与两剂方案的系统综述
该系统综述检索四个数据库2000年1月至2019年7月文献,纳入33篇同行评议论文和1篇会议摘要,评估儿童普种非活甲肝疫苗一剂与两剂方案对发病率、死亡率、严重程度、疫苗效果、效力及抗体持久性的影响。结果显示两剂方案免疫持久性至少15年,一剂方案证据有限,结论认为需两剂以确保长期保护。
要点
- 两剂普种方案疫苗效果3-5年内≥95%,效力0.1-7.5年>98%。
核心结论
- 两剂儿童普种非活甲肝疫苗证据充分,可确保长期保护,一剂方案长期免疫持久性证据不足。
研究设计与样本
- 系统文献综述,检索四个电子数据库2000年1月至2019年7月发表的文献,共筛选3739条记录,纳入33篇同行评议论文和1篇会议摘要。
主要发现
- 引入普种方案后所有年龄组甲肝发病率及相关结局快速下降,两剂方案持续至少14年,一剂方案持续至少6年(按各自研究时长)。
- 两剂方案疫苗效果3-5年内≥95%,一剂方案疫苗效力0.1-7.5年>98%。
关键数值与推荐
- 两剂方案疫苗效果≥95%(3-5年观察期)。
- 一剂方案疫苗效力>98%(0.1-7.5年观察期)。
临床怎么用
- 基于当前证据,儿童普种非活甲肝疫苗应采用两剂方案以确保长期保护。
- 实施一剂普种方案的国家需持续开展流行病学监测,以评估长期免疫持久性和加强剂需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis A virus (HAV) is a global health concern as outbreaks continue to occur. Since 1999, several countries have introduced universal vaccination (UV) of children against HAV according to approved two-dose schedules. Other countries have implemented one-dose UV programs since 2005; the long-term impact of this schedule is not yet known. METHODS: We conducted a systematic literature search in four electronic databases for data published between January 2000 and July 2019 to assess evidence for one-dose and two-dose UV of children with non-live HAV vaccines and describe their global impact on incidence, mortality, and severity of hepatitis A, vaccine effectiveness, vaccine efficacy, and antibody persistence. RESULTS: Of 3739 records screened, 33 peer-reviewed articles and one conference abstract were included. Rapid declines in incidence of hepatitis A and related outcomes were observed in all age groups post-introduction of UV programs, which persisted for at least 14 years for two-dose and six years for one-dose programs according to respective study durations. Vaccine effectiveness was ≥95% over 3-5 years for two-dose programs. Vaccine efficacy was >98% over 0.1-7.5 years for one-dose vaccination. Antibody persistence in vaccinated individuals was documented for up to 15 years (≥90%) and ten years (≥74%) for two-dose and one-dose schedules, respectively. CONCLUSION: Experience with two-dose UV of children against HAV is extensive, demonstrating an impact on the incidence of hepatitis A and antibody persistence for at least 15 years in many countries globally. Because evidence is more limited for one-dose UV, we were unable to draw conclusions on immune response persistence beyond ten years or the need for booster doses later in life. Ongoing epidemiological monitoring is essential in countries implementing one-dose UV against HAV. Based on current evidence, two doses of non-live HAV vaccines are needed to ensure long-term protection.
引用
- Andani A, van Damme P, Bunge EM, et al. One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. Vaccine. 2021. PMID: 33526283. doi:10.1016/j.vaccine.2021.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。